WO1997028265A1 - Immunisation contre la rougeole par inoculation d'unites de transcription de l'adn - Google Patents
Immunisation contre la rougeole par inoculation d'unites de transcription de l'adn Download PDFInfo
- Publication number
- WO1997028265A1 WO1997028265A1 PCT/US1997/001982 US9701982W WO9728265A1 WO 1997028265 A1 WO1997028265 A1 WO 1997028265A1 US 9701982 W US9701982 W US 9701982W WO 9728265 A1 WO9728265 A1 WO 9728265A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- antigen
- measles virus
- transcription unit
- product
- Prior art date
Links
- 238000013518 transcription Methods 0.000 title claims abstract description 122
- 230000035897 transcription Effects 0.000 title claims abstract description 122
- 230000003053 immunization Effects 0.000 title claims abstract description 35
- 201000005505 Measles Diseases 0.000 title claims description 29
- 238000002649 immunization Methods 0.000 title claims description 22
- 238000011081 inoculation Methods 0.000 title description 59
- 239000000427 antigen Substances 0.000 claims abstract description 135
- 102000036639 antigens Human genes 0.000 claims abstract description 135
- 108091007433 antigens Proteins 0.000 claims abstract description 135
- 241000712079 Measles morbillivirus Species 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 68
- 241000124008 Mammalia Species 0.000 claims abstract description 43
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 47
- 239000011324 bead Substances 0.000 claims description 25
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 24
- 101710154606 Hemagglutinin Proteins 0.000 claims description 23
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 23
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 23
- 101710176177 Protein A56 Proteins 0.000 claims description 23
- 239000010931 gold Substances 0.000 claims description 23
- 229910052737 gold Inorganic materials 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 239000000185 hemagglutinin Substances 0.000 claims description 21
- 238000012384 transportation and delivery Methods 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 12
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 8
- 108010059722 Viral Fusion Proteins Proteins 0.000 claims description 7
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 230000028996 humoral immune response Effects 0.000 claims description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 102000007982 Phosphoproteins Human genes 0.000 claims description 3
- 108010089430 Phosphoproteins Proteins 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 208000005647 Mumps Diseases 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 241000702670 Rotavirus Species 0.000 claims description 2
- 206010043376 Tetanus Diseases 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 208000010805 mumps infectious disease Diseases 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 201000005404 rubella Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 108060003393 Granulin Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract description 6
- 108020004414 DNA Proteins 0.000 description 189
- 108091061763 Triple-stranded DNA Proteins 0.000 description 42
- 241000699670 Mus sp. Species 0.000 description 40
- 230000003472 neutralizing effect Effects 0.000 description 36
- 241000283973 Oryctolagus cuniculus Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 21
- 238000006386 neutralization reaction Methods 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 17
- 241000282553 Macaca Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 241000701022 Cytomegalovirus Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 8
- 230000003187 abdominal effect Effects 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000002123 temporal effect Effects 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000282560 Macaca mulatta Species 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 5
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229960000187 tissue plasminogen activator Drugs 0.000 description 5
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 101710169105 Minor spike protein Proteins 0.000 description 4
- 101710081079 Minor spike protein H Proteins 0.000 description 4
- 108010006025 bovine growth hormone Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 229940015418 ketaset Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940069575 rompun Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 241000712045 Morbillivirus Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 229910052734 helium Inorganic materials 0.000 description 3
- 239000001307 helium Substances 0.000 description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 229940065638 intron a Drugs 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 229920002799 BoPET Polymers 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000005041 Mylar™ Substances 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101900237959 Measles virus Hemagglutinin glycoprotein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 241001428894 Small ruminant morbillivirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010892 electric spark Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 208000012965 maculopapular rash Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000029302 virus maturation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- Figure 3A is a graph depicting temporal curves of neutralization titers of antibodies raised in mice by gene gun inoculation of H DNA. DNA deliveries are indicated on dotted lines. Each curve represents data for an individual animal.
- the macaques were anaesthetized with Ketaset/Rompun (ketamine) and their target areas were prepared. Each macaque was either inoculated intradermally in the back or inoculated with a gene gun at the abdominal epidermis. The gene gun method used is described in Example 3 above, with each macaque receiving 1 ⁇ g DNA per delivery at a pressure of 400 p.s.i.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne des procédés et des compositions utilisés pour immuniser un mammifère contre le virus de la rougeole. Ledit procédé consiste à introduire dans le mammifère au moins un produit de transcription de l'ADN comprenant de l'ADN codant pour un antigène du virus de la rougeole lié activement à l'ADN qui est une région de promotrice, et ce afin de produire l'expression de l'antigène et de provoquer une réponse immunitaire. La réponse immunitaire ainsi provoquée peut assurer une protection contre la maladie due au virus de la rougeole. L'hôte peut être n'importe quel mammifère dont l'humain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU21189/97A AU2118997A (en) | 1996-02-05 | 1997-02-05 | Measles immunization by dna transcription unit inoculation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59697796A | 1996-02-05 | 1996-02-05 | |
| US08/596,977 | 1996-02-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997028265A1 true WO1997028265A1 (fr) | 1997-08-07 |
| WO1997028265A9 WO1997028265A9 (fr) | 1997-10-30 |
Family
ID=24389529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/001982 WO1997028265A1 (fr) | 1996-02-05 | 1997-02-05 | Immunisation contre la rougeole par inoculation d'unites de transcription de l'adn |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2118997A (fr) |
| WO (1) | WO1997028265A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750005B2 (en) | 2003-02-13 | 2010-07-06 | Sanofi-Aventis Deutschland Gmbh | Substituted hexahydropyrazino [1,2-A] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992008789A1 (fr) * | 1990-11-20 | 1992-05-29 | Virogenetics Corporation | Vaccin contenant un poxvirus recombine renfermant de l'adn de virus morbilleux |
| WO1993019183A1 (fr) * | 1992-03-23 | 1993-09-30 | University Of Massachusetts Medical Center | Procede d'immunisation par inoculation d'une unite de transcription d'adn |
| WO1995020660A2 (fr) * | 1994-01-27 | 1995-08-03 | University Of Massachusetts Medical Center | Immunisation par inoculation d'une unite de transcription d'adn |
-
1997
- 1997-02-05 AU AU21189/97A patent/AU2118997A/en not_active Abandoned
- 1997-02-05 WO PCT/US1997/001982 patent/WO1997028265A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992008789A1 (fr) * | 1990-11-20 | 1992-05-29 | Virogenetics Corporation | Vaccin contenant un poxvirus recombine renfermant de l'adn de virus morbilleux |
| WO1993019183A1 (fr) * | 1992-03-23 | 1993-09-30 | University Of Massachusetts Medical Center | Procede d'immunisation par inoculation d'une unite de transcription d'adn |
| WO1995020660A2 (fr) * | 1994-01-27 | 1995-08-03 | University Of Massachusetts Medical Center | Immunisation par inoculation d'une unite de transcription d'adn |
Non-Patent Citations (2)
| Title |
|---|
| FOOKS A R ET AL: "High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: Induction of an MHC-1-restricted CTL response and protection in a murine model.", VIROLOGY 210 (2). 1995. 456-465. ISSN: 0042-6822, XP000652343 * |
| GELDER, C. M. ET AL: "Human CD4+ T-cell recognition of influenza A virus hemagglutinin after subunit vaccination", J. VIROL. (1996), 70(7), 4787-4790 CODEN: JOVIAM;ISSN: 0022-538X, July 1996 (1996-07-01), XP000655051 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750005B2 (en) | 2003-02-13 | 2010-07-06 | Sanofi-Aventis Deutschland Gmbh | Substituted hexahydropyrazino [1,2-A] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2118997A (en) | 1997-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020063370A2 (fr) | Composition immunitaire, son procédé de préparation et application associée | |
| Kodihalli et al. | Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin | |
| JP5008244B2 (ja) | 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー | |
| US8372963B2 (en) | RSV F-protein and its use | |
| US5698202A (en) | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier | |
| EP0390799B1 (fr) | Virus syncytial respiratoire: vaccins | |
| EP0832253B1 (fr) | Vaccins a acides nucleiques du virus respiratoire syncytial | |
| JP2716503B2 (ja) | ヒト呼吸系シンシチウムウイルスの糖蛋白類の免疫原性セグメントを含有するキメラ糖蛋白類 | |
| JP3602448B2 (ja) | 核酸呼吸器シンシチウムウイルスワクチン | |
| HUT65366A (en) | Expression of specific immunogens using viral antigens | |
| US7645455B2 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
| US6077514A (en) | Attenuated respiratory syncytial virus | |
| JP6952112B2 (ja) | 新規なｅｈｖ挿入部位ｏｒｆ７０ | |
| CA2624291A1 (fr) | Composition immunologique d'acides nucleiques contre le metapneumovirus humain | |
| US20220323568A1 (en) | Rsv vaccines and methods of production and use thereof | |
| EP0784486B1 (fr) | Interleukine-12 utilisee en tant qu'adjuvant pour vaccins contre les paramyxoviridae | |
| JP7642608B2 (ja) | ハンタウイルス抗原性組成物 | |
| WO1997028265A1 (fr) | Immunisation contre la rougeole par inoculation d'unites de transcription de l'adn | |
| WO1997028265A9 (fr) | Immunisation contre la rougeole par inoculation d'unites de transcription de l'adn | |
| KR20010080863A (ko) | 마진 바이러스 또는 인간 호흡기 합포체 바이러스서브그룹 비에서 감쇠 담당 돌연변이 | |
| EP1171454B1 (fr) | Acides nucleiques et polypeptides de lyssavirus chimeres | |
| JP2002501369A (ja) | Ｆｉｖワクチン | |
| US7238672B1 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
| US20220193224A1 (en) | Rsv-based virus-like particles and methods of production and use thereof | |
| WO1997038138A1 (fr) | Virus respiratoire syncytial attenue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| COP | Corrected version of pamphlet |
Free format text: PAGE 20,DESCRIPTION,REPLACED BY A NEW PAGE BEARING THE SAME NUMBER;PAGES 1/8-8/8,DRAWINGS,REPLACED BY NEW PAGES 1/7-7/7;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97527949 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |